Dymon Asia Capital (Singapore) Pte. Ltd. Zai Lab LTD Transaction History
Dymon Asia Capital (Singapore) Pte. Ltd.
- $416 Million
- Q4 2024
A detailed history of Dymon Asia Capital (Singapore) Pte. Ltd. transactions in Zai Lab LTD stock. As of the latest transaction made, Dymon Asia Capital (Singapore) Pte. Ltd. holds 20,000 shares of ZLAB stock, worth $619,000. This represents 0.13% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$619,000% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding ZLAB
# of Institutions
161Shares Held
50.2MCall Options Held
103KPut Options Held
439K-
Janus Henderson Group PLC London, X06.57MShares$203 Million0.09% of portfolio
-
Capital World Investors Los Angeles, CA6.01MShares$186 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA3.65MShares$113 Million0.03% of portfolio
-
Clearbridge Investments, LLC New York, NY3.28MShares$102 Million0.11% of portfolio
-
Morgan Stanley New York, NY3.17MShares$98 Million0.01% of portfolio
About Zai Lab Ltd
- Ticker ZLAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,908,704
- Market Cap $3.03B
- Description
- Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...